A new study has shown that the drug velagliflozin may be an effective tool for controlling laminitis risk factors in ponies. The drug is capable of managing equine's insulin dysregulation; current treatment for insulin dysregulation includes restricting pasture and feeding a diet low in non-structural carbohydrates.
The research team was led by Dr. Martin Sillence of Queensland University and included Alexandra Meier, Melody de Laat, D. Fitzgerald and Dania Reiche. The scientists studied the effectiveness and safety of the drug over a 16-week trial and an additional month of withdrawal. The research used 24 ponies that had insulin dysregulation, a component of metabolic syndrome, which has been linked to laminitis. Half of the ponies received velagliflozin; the others received a placebo. All ponies were kept on an amount of feed to keep them fat (which would not be recommended for horses at risk of laminitis).
To determine the safety of the drug, the ponies were monitored daily, including a blood draw to determine blood glucose and biochemistry. The effectiveness of the drug was determined by its ability to reduce insulin spikes.
Velagliflozin was well tolerated by all subjects in the study and caused no adverse effects; the maximum insulin concentrations fell over time, putting the ponies below the risk threshold for laminitis.
The study can be read here.
Read more at HorseTalk.
New to the Paulick Report? Click here to sign up for our daily email newsletter to keep up on this and other stories happening in the Thoroughbred industry.
Copyright © 2019 Paulick Report.